Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess the Efficacy, Safety and Pharmacokinetics of Risedronate Upon Oral Administration of a 35 mg Delayed-Release, a 50 mg Delayed-Release or a 35 mg Immediate-Release Administered Weekly for 13 Weeks to Postmenopausal Women

NCT00577720 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00577720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess the Efficacy, Safety and Pharmacokinetics of Risedronate Upon Oral Administration of a 35 mg Delayed-Release, a 50 mg Delayed-Release or a 35 mg Immediate-Release Administered Weekly for 13 Weeks to Postmenopausal Women
Lead sponsor
Warner Chilcott
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
January 31, 2007
Enrollment
181 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal women